Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05207670 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
A Phase 2 study of Non-Hodgkin Lymphoma, sponsored by Genentech.
- Active
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT05207670: Active Phase 2 study of Non-Hodgkin Lymphoma, sponsored by Genentech.
NCT05207670 is a Phase 2 study of Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Genentech. The registered enrollment target is 320 participants, above the 165-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (94% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05207670, a Phase 2 study of Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \[NHL\]).
Conditions Studied
Interventions
- DRUG Tocilizumab
- DRUG Mosunetuzumab (Cohorts A-C)
- DRUG Mosunetuzumab (Cohorts D-E)
Study Locations (20)
Florida
- SCRI Florida Cancer Specialists South - Fort Myers
- Mayo Clinic Jacksonville - PPDS - Jacksonville
- Cancer Specialists of North Florida - Jacksonville - Jacksonville
- Florida Cancer Specialists - NORTH - SCRI - PPDS - St. Petersburg
- Florida Cancer Specialists - EAST - SCRI - PPDS - West Palm Beach
Alabama
- Infirmary Cancer Care - Mobile
Alaska
- Alaska Oncology & Hematology, LLC - Anchorage
Arizona
- Mayo Clinic Arizona - Phoenix
California
- City of Hope - Duarte
Colorado
- Rocky Mountain Cancer Centers (Aurora) - USOR - Aurora
Delaware
- Medical Oncology Hematology Consultants - Newark
Iowa
- Mission Blood and Cancer - MercyOne Cancer Center - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
What the registry record for NCT05207670 still lists
NCT05207670 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 165-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (94% higher).
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Tocilizumab is the first listed.
NCT05207670 names 20 study sites across 16 states, led by Florida, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT05207670 about?
NCT05207670 is a clinical study titled "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies". This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \[NHL\]).
What is the current status of trial NCT05207670?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2022-02-01. Estimated completion is 2028-07-31.
What conditions does trial NCT05207670 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05207670?
The interventions under investigation include: Tocilizumab (DRUG), Mosunetuzumab (Cohorts A-C) (DRUG), Mosunetuzumab (Cohorts D-E) (DRUG).
Who is sponsoring clinical trial NCT05207670?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05207670 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05207670's enrollment target sits among peer trials
320 13th of 106 higher than 94 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI